Skip to main content

Combination Therapy in Rheumatoid Arthritis

Dr. Arthur Kavanaugh | ACR 2026
 

Transcription

Hi, this is Dr. Artie Kavanaugh coming to you from ACR 2026 Convergence for RheumNow. My perspective — this talk is going to be on combination therapy, specifically combination therapy in rheumatoid arthritis.

Fascinating topic that has a deep history based in the 80s. There were many animal models of rheumatoid arthritis which suggested that combinations of different targeted therapies is probably the way to go. Thinking of TNF inhibition and IL-1 inhibition in animal models, that was fantastic. You not only saw additive benefit, you saw synergistic benefit — you saw the complete abrogation of inflammation and damage in animal models.

Of course, as we all know, in humans the experience was much different. In studies that looked at TNF inhibition plus IL-1 inhibition, and TNF inhibition with T-cell inhibitor therapy with abatacept, the results were dismal. There was not clinical benefit, but there was a readout, and that was increased infection. So since that time — and this is now going back to the early 90s — there's been black boxes that say do not combine biologic agents.

Well, times are evolving, and thanks to collaboration with our colleagues in ulcerative colitis and a pivotal study called VEGA, that showed that combination of a TNF inhibitor golimumab plus an IL-23 inhibitor guselkumab did what we had always hoped combination therapy would do — and that is additive benefit without additive toxicity.

Now rheumatoid arthritis has kind of lagged that a little bit. There are studies going on in ulcerative colitis, in IBD, and also in ankylosing spondylitis, in psoriatic arthritis — not so far in rheumatoid arthritis. I think we've still been a little bit gun-shy.

So there are a couple of abstracts at this meeting with small numbers of patients. One from new RA patients, and this abstract 1402, which looked at abatacept plus an anti-CD38 monoclonal antibody, daratumumab — three patients only, severe refractory disease. The results really kind of didn't knock your socks off, even though it's only three patients. There was an improvement, and they are very refractory patients, and there didn't seem to be a lot of toxicity — but there was some. Daratumumab, an anti-CD38 monoclonal antibody approved for certain kinds of cancer, is a strong therapy directed at cells bearing CD38, which is widely spread. So looking at these results, I would say I'm not sure that I'm excited about this particular approach, but I think it's great to see the idea of combination therapy opening up.

And I think we're at the point where we'll see anecdotes such as these. In the Leuven study, TNF inhibitors and JAK inhibitors were combined and it seemed to not have a safety signal. Of course, we need more patients, but I think we'll see that certain combinations get knocked out of the running early and others need to be studied further in more rigorous study design.

So combination therapy may be coming back in rheumatoid arthritis. This is Dr. Artie Kavanaugh coming to you from ACR 2026 Convergence for RheumNow.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×